ResearchMoz

Espicom Market Research Reports

With over 30 years of continuous research and editorial experience in the global health industry, Espicom is one of the longest established independent business intelligence providers operating today. 
Espicom produces original analysis, news and forecasts using its skilled and experienced team of more than 30 full-time in-house analysts, researchers and editorial experts. With a combined experience of over 200 years they cover key disciplines including pharmacology, biosciences, economics statistics and languages. In addition, a select group of experts are on hand in respect of specialist scientific/technology areas. We do not use freelancers or subcontractors to produce our class leading subscription and intelligence services. This gives us control and you confidence. 

List of reports from Espicom

Displaying 1 to 30 (of 156 records)
The Pharmaceutical Market: Greece
Apr 2014  
THE PHARMACEUTICAL MARKET: GREECE - REVIEW The immediate threat of a Greek default and eurozone exit was reduced as the outcome of the legislative elections in June had a much more benign outcome than many feared. A n exit would have - and could still be - disastrous for drugmakers operating in the market. But even Greece staying in the monetary union means the government must...
$1295
The Pharmaceutical Market: Bahrain
Apr 2014  
Pharmaceuticals & Healthcare Report We expect Bahrain's pharmaceutical market values to grow steadily over the coming years. Key drivers will be volume-based, as the growing population increasingly requires more sophisticated treatments for lifestyle diseases and as healthcare provision expands and modernises . However, w hile some investment has been made into the local...
$1295
The Pharmaceutical Market: Cambodia
Apr 2014  
Cambodia Pharmaceuticals & Healthcare Report Lacklustre efforts by the government to boost healthcare means that the Cambodia will be the least attractive to pharmaceutical investors as compared to its South East Asian peers as the population are unable to afford new treatments. Over the longer term we expect such trends to change and active participation in the...
$1295
The Pharmaceutical Market: Sri Lanka
Apr 2014  
Sri Lanka Pharmaceuticals & Healthcare Report Sri Lanka's negative pharmaceutical trade balance is expected to widen over the next five years. In an attempt to reduce medical costs, the government said in its 2011 budget that pharmaceutical products will be exempt from the port and airport levy, with the changes relating to drugs, medical devices and equipment. Although...
$1295
The Pharmaceutical Market: Czech Republic
Apr 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN CZECH REPUBLIC The recent measures proposed by the Czech Republic's Ministry of Health will, in all likelihood, negatively affect the Czech pharmaceutical market. The introduction of reimbursement ceilings, blind bidding auctions and preferential prescribing will squeeze drugmakers' margins and shift some of the burden of healthcare...
$1295
The Pharmaceutical Market: Denmark
Apr 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN DENMARK The macroenvironment for the Danish pharmaceutical industry is improving. The centre-left coalition, of the Social Democratic Party, the Socialist People's Party and the Social Liberal Party, took office in October 2011. Denmark suffered a deep recession and economic recovery is stalling with negative GDP growth projected for...
$1295
The Pharmaceutical Market: Venezuela
Apr 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN VENEZUELA We expect the Venezuelan government to continue its foreign currency and import control policies in Q412 and the local market will endure further government restrictions on pharmaceutical and healthcare industry. Multinationals will have the potential revenue-generation opportunities from Venezuela's increasing reliance on...
$1295
The Pharmaceutical Market: Iraq
Apr 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN IRAQ Years of underinvestment have taken their toll on the Iraqi healthcare market, as have international sanctions and deterioration of healthcare infrastructure due to war. Still an unpopular figure on the international market, Iraq's trade partners are few and far between - although Iraq does have a strong bargaining chip: its oil...
$1295
The Pharmaceutical Market: Lithuania
Apr 2014  
THE PHARMACEUTICAL MARKET: LITHUANIA- REVIEW We continue to hold our subdued outlook for the Lithuanian pharmaceuticals market during the next few years, on account of the changing economic and demographic situation. We expect limited low single digit growth in 2012 , with the market expected to increase by a local currency margin of 2.5% year-on-year (y-o-y) to reach LTL1.6 8...
$1295
The Pharmaceutical Market: Saudi Arabia
Apr 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SAUDI ARABIA Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators....
$1295
The Pharmaceutical Market: Morocco
Apr 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN MOROCCO Morocco's subsidised health insurance scheme,Régime d'Assistance Médicale (RAMED),launched in March 2012,is experiencing early-stage difficulties with its target to increasehealthcare accessibilityto those on low incomes. This is to be expected, given the evidence of bribery and corruption, and the shortage of...
$1295
The Pharmaceutical Market: Serbia
Apr 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SERBIA While the market is small in terms of absolute numbers, relative per capita spending on medicines is expected to improve over the long term. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that...
$1295
Understanding Myanmars Regional Healthcare Markets
Mar 2014  
Commercial opportunities in Myanmar's healthcare sector are mainly derived from its large unmet medical needs and underinvestment. However, we maintain that significant improvements are required if Myanmar is to realise its ambitious public health insurance scheme. In addition, political uncertainties from the upcoming election in 2015 may also deter investors over the short term....
$935
Understanding South Africas Regional Healthcare Markets
Mar 2014  
With a new National Health Insurance system being implemented, what will the effects be on the under-resourced public sector and the expensive private sector? And what changes can be seen at the varied regional and provincial levels? Any assessment of South Africa must consider the potential variations across Eastern Cape, Free State, Gauteng, KwaZulu-Natal, Limpopo, Mpumalanga, North...
$935
Medical Device Pricing & Reimbursement 2014
Mar 2014  
Provides insight into medical device pricing and reimbursement systems and latest regulations across 17 key countries! This guide provides everything you could need to know about medical device pricing and reimbursement in 17 established and emerging economies. It examines the increasing role that health technology assessment plays in the reimbursement decision-making process and...
$995
The Pharmaceutical Market: Moldova
Mar 2014  
Moldova Pharmaceuticals & Healthcare Report Given the high level of reliance on out-of-pocket payments, the growth of the Moldova's pharmaceutical market is expected to be shaped by the prevailing economic conditions, both at home and abroad, on account of the importance of remittances to the country's GDP. For 2012, we expect the market's value to increase at a local...
$1295
The Pharmaceutical Market: Russia
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN RUSSIA The Russian pharmaceutical market remains a powerhouse in the Emerging Europe region . The country has by far the larg est population in the region. I ts resource s -driven economic growth is funding both private and public spending on medicines and healthcare services. The country's World Trade Organisation (WTO) accession has...
$1295
The Pharmaceutical Market: Spain
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SPAIN The sharp drop in public pharmaceutical expenditure in Spain in the first four months of 2012 serves as a warning for the continuation of a fall in spending on medicines in the remainder of the year. BMI notes that this does not bode well for drugmakers selling their products in Spain as the success of the implemented policies may...
$1295
The Pharmaceutical Market: United Kingdom
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN UNITED KINGDOM Drugmakers and governments will increasingly enter agreements that provide some form of risk- sharing or price protection for new drugs. Since most European governments, including the UK authorities, are focussing on cost containment in the healthcare sector, alternative pricing schemes for medicines allow for budget...
$1295
The Pharmaceutical Market: India
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN INDIA The outlook for India's patented drug market is not promising. The primary reason why sales of these products will not grow swiftly is the country's intellectual property (IP) regime, which is well below international standards. It does not recognise incremental improvements and as such few medicines receive exclusivity. The outlook...
$1295
The Pharmaceutical Market: Finland
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN FINLAND The macroenvironment for the Finnish pharmaceutical industry is improving.Politically, the new six-party coalition is larger and represents a broader spectrum of opinion than is usual, which could make it unstable. However, the Economist Intelligence Unit (EIU) believes that it will last out its four-year term. Economically,...
$1295
The Pharmaceutical Market: Belarus
Mar 2014  
Pharmaceuticals & Healthcare Report We remain largely pessimistic about the Belarus' pharmaceutical market development in the short term at least. While the government remains committed to boosting domestic pharmaceutical output over the coming years, with authorities in manufacturing joint venture (JV) discussions with a number of countries, the devalued rouble, high...
$1295
The Pharmaceutical Market: Israel
Mar 2014  
THE PHARMACEUTICAL MARKET: ISRAEL- REVIEW Although Israel claims its very efficient healthcare system means it does not need to spend as much of its GDP on provision (some 7.6% was spent on this purpose in 2011), in reality the government's fiscal austerity and sick funds traditionally keep the most expensive innovative drugs and treatments unavailable. Additionally, as...
$1295
The Pharmaceutical Market: Switzerland
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SWITZERLAND While the patent cliff and the consequent availability of generic drugs, as well as price cuts on generic medicines and their increasing affordability, will work towards increasing the consumption of generic medicines in Switzerland, BMI believes the government needs to do more to alter patients' attitudes towards these...
$1295
The Pharmaceutical Market: Brazil
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN BRAZIL The Brazilian pharmaceutical market remains our favourite regional market in Latin America due to its large market size and strong domestic demand for innovative, high-tech products. The government i s increasing ly invest ing in the healthcare sector and pharmaceutical industry to reduce the financial burden of diseases , and the...
$1295
The Pharmaceutical Market: Kuwait
Mar 2014  
Kuwait Pharmaceuticals & Healthcare Report Kuwait's small population, and the fact that many residents are expatriates means that the country's healthcare market is closely linked to that of neighbouring Arab nations. Private healthcare accounts for around a fifth of total spending, and the government funds treatment for many nationals abroad. As Kuwait's population...
$1295
The Pharmaceutical Market: Malaysia
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN MALAYSIA Malaysia ' s healthcare sector is showing strong signs of growth, with increased internal and investment in pharmaceutical manufacturing facilities in a move to boost exports. Key growth areas include biotechnology; namely drug discovery, new product development , technology acquisition and licensing ; generic drug production;...
$1295
The Pharmaceutical Market: Portugal
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN PORTUGAL Portugal 's pharmaceutical and healthcare sector has been transformed since the intervention of the EU, IMF and ECB as part of the country's EUR78bn economic rescue package approved in May 2011 . The latest review states that Portugal has already made considerable savings in the healthcare sectors, with changes such as the...
$1295
The Pharmaceutical Market: Egypt
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN EGYPT As anticipated by BMI, Egyptian President Mohammad Morsi's relative success in his first100days in officehighlights a degree of political and economic stability,which we believehas resulted in a final resolution of the medicines pricing system. We highlight that our expectation of the government imposing pharmaceutical price caps...
$1295
The Pharmaceutical Market: Iran
Mar 2014  
OVERVIEW OF THE PHARMACEUTICAL MARKET IN IRAN We caution that our forecasts for the Iranian pharmaceutical market are at considerable risk due to runaway inflation and political risks. We also point out that the official exchange rate does not follow the trends in the black market, which further distorts market valuations. While our local currency forecast for the market's...
$1295
 
Displaying 1 to 30 (of 156 records)

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com

Popular Publishers

Transparency Market Research
ICD Research
Technavio
 
GBI Research
Winter Green Research
GlobalData